Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: A phase II study

Cancer Investigation

Volumn 28, Issue 8, 2010, Pages 820-827

  Orditura, Michele ^a   Galizia, Gennaro ^a   Napolitano, Vincenzo ^a   Martinelli, Erika ^a   Pacelli, Roberto ^b   Lieto, Eva ^a   Aurilio, Gaetano ^a   Vecchione, Loredana ^a   Morgillo, Floriana ^a   Catalano, Giuseppe ^a   Ciardiello, Fortunato ^a   Genio, Alberto Del ^a   Martino, Natale Di ^a   De Vita, Ferdinando ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cisplatin; Esophageal cancer; Paclitaxel; Preoperative chemoradiotherapy

Indexed keywords

CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BRONCHOSCOPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; GRANULOCYTOPENIA; HEART ATRIUM FIBRILLATION; HUMAN; MALE; NAUSEA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; ADENOCARCINOMA; BIOPSY; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; DRUG ADMINISTRATION; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATIENT SELECTION; PROCEDURES; PROGNOSIS; THROMBOCYTE COUNT; TIME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PATIENT SELECTION; PLATELET COUNT; PROGNOSIS; RADIOTHERAPY; SURVIVAL RATE; TIME FACTORS;

EID: 77956636233     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357901003630926     Document Type: Article

References (38)

1. Portale, G.; Hagen, J.A.; Peters, J.M.; Chan, L.S.; DeMeester, S.R.; Gandamihardja, T.A.; DeMeester, T.R. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg 2006, 202 (4), 588-596.
2. Bosset, J.F.; Lorchel, F.; Mantion, G.; Buffet, J.; Créhange, G.; Bosset, G.; Chaigneau, L.; Servagi, S. Radiation and chemoradiation therapy for esophageal adenocarcinoma. J Surg Oncol 2005, 92, 239-245.
3. Gebski, V.; Burmeister, B.; Smithers, B.M.; Foo, K.; Zalcberg, J.; Simes, J. Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007, 8, 226-234.
4. Kaklamanos, I.G.; Walker, G.R.; Ferry, K.; Franceschi, D.; Livingstone, A.S. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analyses of randomized clinical trials. Ann Surg Oncol 2003, 10, 754-761.
5. Urschel, J.D.; Vasan, H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003, 185, 538-543.
6. Fiorica, F., Di Bona, D., Schepis, F.; Licata, A.; Shahied, L.; Venturi, A.; Falchi, A.M.; Craxì, A.; Cammà, C. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and metaanalyses. Gut 2004, 53, 925-930.
7. De Vita, F.; Di Martino, N.; Orditura, M.; Cosenza, A.; Galizia, G.; Del Genio, A.; Catalano, G. Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: a phase II study. Chest 2002, 122, 1302-1308.
8. Meluch, A.A.; Greco, F.A.; Gray, J.R.; Thomas, M.; Sutton, V.M.; Davis, J.L.; Kalman, L.A.; Shaffer, D.W.; Yost, K.; Rinaldi, D.A.; Hainsworth, Preoperative therapy with concurrent paclitaxel/ carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 2003, 9, 251-260.
9. Henry, L.R.; Goldberg, M.; Scott, W.; Konski, A.; Meropol, N.; Freedman, G.; Weiner, L.M.; Watts, P.; Beard, M.; McLaughlin, S.; Cheng, J.D.; et al. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. Ann Surg Oncol 2006, 13, 214-220.
10. Roof, K.S.; Coen, J.; Lynch, T.J.; Wright, C.; Fidias, P.; Willett, C.G.; Choi, N.C. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2006, 65, 1120-1128.
11. Lowy, A.M.; Firdaus, I.; Roychowdhury, D.; Redmond, K.; Howington, J.A.; Sussman, J.J.; Safa, M.; Ahmad, S.A.; Reed, M.F.; Rose, P.; James, L.; Jazieh, A.R. A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma. Am J Clin Oncol 2006, 6, 551-561.
12. van de Schoot, L.; Romme, E.A.P.M.; van dee Sangen, M.J.; Creemers, G.J.; van Lijnschoten, G.; van Driel, O.J.; Rutten, H.J.; Nieuwenhuijzen, G.A. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer. Ann Surg Oncol 2008, 1, 88-95.
13. Blanke, C.D.; Choy, H.; Teng, M.; Beauchamp, R.D.; Leach, S.; Roberts, J.; Washington, K.; Johnson, D.H. Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. Semin Radiat Oncol 1999, 2, 43-52. (Pubitemid 29190410)
14. Urba, S.G.; Orringer, M.B.; Turrisi, A.; Iannettoni, M.; Forastiere, A.; Strawderman, M. A phase II trial of preoperative cisplatin, paclitaxel, and radiation therapy before trans-hiatal esophagectomy in patients with locoregional esophageal cancer. J Clin Oncol 2001, 19, 248.
15. Safran, H.; Gaissert, H.; Akerman, P.; Hesketh, P.J.; Chen, M.H.; Moore, T.; Koness, J.; Graziano, S.; Wanebo, H.J. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001, 19, 1-7. (Pubitemid 32233795)
16. Adelstein, D.J.; Rice, T.W.; Rybicki, L.A.; Larto, M.A.; Ciezki, J.; Saxton, J.; DeCamp, M.; Vargo, J.J.; Dumot, J.A.; Zuccaro, G. Does paclitaxel improve chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000, 18, 2032-2039.
17. van Meerten, E.; Muller, K.; Tilanus, H.W.; Siersema, P.D.; Eijkenboom, W.M.; van Dekken, H.; Tran, T.C.; van der Gaast, A. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with esophageal cancer: a phase II study. Br J Cancer 2006, 94, 1389-1394.
18. Boone, J.; Livestro, D.P.; Elias, S.G.; Borel Rinkes, I.H.; van Hillegersberg, R. International survey on esophageal cancer: part II staging and neoadjuvant therapy. Dis Esophagus 2009, 22 (3), 203-210.
19. Noble, F.; Bailey, D.; SWCIS Upper Gastrointestinal Tumour Panel; Tung, K.; Byrne, J.P. Impact of integrated PET/CT in the staging of oesophageal cancer: a UK population-based cohort study. Clin Radiol 2009, 64 (7), 699-705.
20. Ngamruengphong, S.; Sharma, V.K.; Nguyen, B.; Das, A. Assessment of response to neoadjuvant therapy in esophageal cancer: an updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography. Dis Esophagus 2009 Jun 9. [Epub ahead of print].
21. Jamil, L.H.; Gill, K.R.; Wallace, M.B. Staging and restaging of advanced esophageal cancer. Curr Opin Gastroenterol 2008, 24 (4), 530-534.
22. Schneider, P.M.; Metzger, R.; Schaefer, H.; Baumgarten, F.; Vallbohmer, D.; Brabender, J.; Wolfgarten, E.; Bollschweiler, E.; Baldus, S.E.; Dienes, H.P.; Hoelscher, A.H. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 2008, 248 (6), 902-908.
23. Omloo, J.M.; Sloof, G.W.; Boellaard, R.; Hoekstra, O.S.; Jager, P.L.; van Dullemen, H.M.; Fockens, P.; Plukker, J.T.; van Lanschot, J.J. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Endoscopy 2008, 40 (6), 464-471.
24. Wong, R.; Malthaner, R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus (Cochrane Review). In: The Cochrane Library 2001, (Issue 4).
25. Ajani, J.A.; Ilson, D.H.; Daugherty, K.; Pazdur, R.; Lynch, P.M.; Kelsen, D.P. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994, 86, 1086-1091.
26. Rowinsky, E.K.; Donehover, R.C. Paclitaxel (Taxol). N Eng J Med 1995, 332, 1004-1013.
27. Ajani, J.A.; Ilson, D.H.; Kelsen, D.P. The activity of paclitaxel in gastrointestinal tumors. Semin Oncol 1995, 12, 46-50.
28. Liebermann, J.; Cook, J.A.; Fisher, J.; Teague, D.; Mitchell, J.B. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994, 86, 441-446.
29. Kim, D.W.; Blanke, C.D.; Wu, H.; Shyr, Y.; Berlin, J.; Beauchamp, R.D.; Chakravarthy, B. Phase II study of preoperative paclitaxel/ cisplatin with radiotherapy in locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2007, 67, 397-404.
30. Lin, C.C., Hsu, C.H., Cheng, J.C.;Wang, H.P.; Lee, J.M.; Yeh, K.H.; Yang, C.H.; Lin, J.T.; Cheng, A.L.; Lee, Y.C. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007, 18, 93-98.
31. Mandard, A.M.; Dalibard, F.; Mandard, J.C.; Marnay, J.; Henry-Amar, M.; Petiot, J.F.; Roussel, A.; Jacob, J.H.; Segol, P.; Samama, G. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal cancer. Cancer 1994,73, 2680-2686.
32. Isenberg, G.; Chak, A.; Canto, M.I.; Levitan, N.; Clayman, J.; Pollack, B.J.; Sivak, M.V Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation. Gastrointest Endosc 1998, 48, 158-163.
33. Willis, J.; Cooper, G.S.; Isenberg, G.; Sivak, M.V.; Levitan, N.; Clayman, J.; Chak, A. Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma. Gastrointest Endosc 2002, 55, 655-661.
34. Castell, F.; Cook, G.J.R. Quantitative techniques in 18FDG-PET scanning in oncology. Br J Cancer 2008, 98, 1597-1601.
35. Dam, H.Q.; Manzone, T.M.; Sagar, W. Evolving role of 18Ffluorodeoxyglucose positron emission tomography in the management of esophageal carcinoma. Surg Oncol Clin N Am 2006, 15, 733-749.
36. Ott, K.;Weber,W.; Siewert, J.R. The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus 2006, 19, 433-442.
37. Erasmus, J.J.; Munden, R.F. The role of integrated computed tomography positron-emission tomography in esophageal cancer: staging and assessment of therapeutic response. Semin Radiat Oncol 2007, 17, 29-37.
38. Kleinberg, L.; Forastiere, A.A. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007, 25, 4110-4117.